Post-Doctoral Researcher in Immuno-Oncology and Cancer Signalling - AC0921
29, rue Henri Koch, Esch-sur-Alzette L-4354, Luxembourg
BAckground and Research Environment
The Luxembourg Institute of Health is offering a postdoctoral position within the Department of Infection and Immunity (group of Immuno-Pharmacology and Interactomics) in the area of cancer cell signalling to carry out a multidisciplinary research project on the involvement of chemokine receptors in glioblastoma.
Tumour growth and dissemination are among the most important aspects in cancer biology. Chemokines are a superfamily of chemo-attractant cytokines playing critical roles in these processes. The biological effects of chemokines are mediated through seven-transmembrane receptors coupled to G proteins (GPCRs). Recently, different chemokine receptors and chemokines, notably atypical chemokine receptors (ACKRs) have been proposed to play a crucial role in glioblastoma, an aggressive malignant brain tumour.
The group of Immuno-Pharmacology and Interactomics investigates the fundamental and clinical implications of chemokine receptors in human biology and immuno-oncology-related processes and inflammatory diseases. The Department of Infection and Immunity located at the House of BioHealth is a basic clinical-translational research entity aiming at understanding the complex mechanisms of infectious and inflammatory processes to enable new ways to diagnose, prevent and cure human diseases. Building on a highly interdisciplinary research environment, its strategy bridges experimental discovery and validation with clinical application and technology development to address major unsolved medical needs in the areas of immune-mediated inflammation, cancer and infectious diseases. The researchers of DII have access to state-of-the-art core facilities including cell culture labs, SPF animal house, confocal microscopy, interactomics, proteomics, genomics, flow cytometry (CyTOF, imaging flow cytometry,...), in vivo imaging, BSL2 and BSL3 facilities.
This project will investigate chemokine receptor functions, signalling and modulation in the context of glioblastoma biology. The research efforts will be directed toward four convergent approaches:
1. Defining the expression profiles of different receptors on tissues and cells derived from glioblastoma patients.
2. Engineering CRISPR-edited cell lines to investigate specific chemokine signalling pathways.
3. Investigating the signalling properties of chemokines towards receptors in vitro and in vivo.
4. Examining the impact of receptor modulation on cell proliferation, migration and survival in vitro and PDOX mouse models.
Chevigné et al.Cancers 2021. https://pubmed.ncbi.nlm.nih.gov/33801414/
Sjoberg et al. Adv. Cancer Res. 2020 https://pubmed.ncbi.nlm.nih.gov/32089166/
Meyrath et al. Nature Communications 2020. https://pubmed.ncbi.nlm.nih.gov/32561830/
Sjoberg et al.Clin Cancer Res. 2019. https://pubmed.ncbi.nlm.nih.gov/30850359/
Willems et al. Oncogene 2019. https://pubmed.ncbi.nlm.nih.gov/30082913/
KEY SKILLS, EXPERIENCE AND QUALIFICATIONS
- PhD in Cellular and Molecular Biology or Oncology with strong expertise in cancer immunology and cellular signalling or pharmacology
- Expertise in experimental lab work using cancer cell lines, signalling profiling, protein–protein interactions, pharmacology, gene expression reporter system, molecular biology, flow cytometry and cell imaging techniques
- Expertise in CRISPR technology, RNAseq, animal experimentation will be considered as an asset
- Independence and self-motivation, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigour, perseverance, strong writing skills
- Fluency in English is mandatory.
Dr. Andy Chevigné, PhD
29 Rue Henri Koch
In Short ...
Contract type : 2-year fixed-term contract
Work hours: Full time- 40h/week
Location: Esch sur Alzette
Start date: as soon as possible
Ref: VD/PDRCS0921/AC/DII INF2
How to apply
Only candidates with a strong track record and demonstrated ability to perform and publish independent research will be considered